Welcome to our dedicated page for Bergenbio AS news (Ticker: BRRGF), a resource for investors and traders seeking the latest updates and insights on Bergenbio AS stock.
Access news coverage and press releases related to BerGenBio ASA (BRRGF), the Norway-based clinical-stage biopharmaceutical company that specialized in developing AXL kinase inhibitors for cancer treatment. BerGenBio completed a merger with Oncoinvent ASA on October 29, 2025, with the combined company now operating as Oncoinvent ASA.
Prior to the merger, BerGenBio's news flow focused on its lead drug candidate Bemcentinib, a selective oral AXL inhibitor investigated in multiple cancer indications including non-small cell lung cancer, acute myeloid leukemia, and various solid tumors. The company received FDA Fast Track designation for Bemcentinib in combination therapy for AXL-positive advanced NSCLC.
Historical news articles and press releases document BerGenBio's clinical trial progress, partnership announcements, regulatory developments, and scientific presentations at major oncology conferences. The company's research contributions to understanding AXL receptor tyrosine kinase biology and its role in cancer drug resistance generated significant scientific publications and conference presentations.
Following the merger, news related to the combined entity appears under Oncoinvent ASA (ticker: ONCIN on Oslo Stock Exchange), which focuses on radiopharmaceutical cancer therapies including the Radspherin platform. Investors seeking current updates should monitor Oncoinvent ASA news sources for developments affecting the merged company structure.
BerGenBio ASA (OSE: BGBIO) has appointed Olav Hellebø as CEO, effective November 21, 2024. Hellebø brings 30 years of pharmaceutical and biotechnology industry experience, including roles at Cytovation ASA, Antev , ReNeuron Group PLC, and Clavis Pharma ASA. He has also held leadership positions at UCB-Celltech, Novartis UK, and Schering-Plough. The company is developing selective AXL kinase inhibitors, with its candidate drug bemcentinib in clinical trials for non-squamous non-small cell lung cancer patients with STK11 gene mutations.
BerGenBio ASA has announced updated preliminary survival data from its ongoing Phase II study of bemcentinib in combination with low dose cytarabine for elderly patients with relapsed Acute Myeloid Leukaemia (AML). The study included an expansion cohort of 27 patients, showing a 31% overall response rate and a median overall survival of 13.3 months. Notably, patients receiving multiple cycles exhibited a 36% complete response rate. Ongoing discussions with FDA and EMA focus on a pivotal trial pathway for this combination therapy.
